UPB (Upstream Bio) Price-to-Tangible-Book : 0.84 (As of Apr. 12, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Price-to-Tangible-Book?

As of today (2025-04-12), Upstream Bio's share price is $7.37. Upstream Bio's Tangible Book per Share of Dec. 2024 for the quarter that ended in Dec. 2024 was $8.77. Hence, Upstream Bio's Price to Tangible Book Ratio of today is 0.84.

The historical rank and industry rank for Upstream Bio's Price-to-Tangible-Book or its related term are showing as below:

UPB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.84 Med: 1.88 Max: 1.88
Current: 0.84

During the past 3 years, Upstream Bio's highest Price to Tangible Book Ratio was 1.88. The lowest was 0.84. And the median was 1.88.

UPB's Price-to-Tangible-Book is ranked better than
84.22% of 1204 companies
in the Biotechnology industry
Industry Median: 2.36 vs UPB: 0.84

A closely related ratio is called PB Ratio. As of today, Upstream Bio's share price is $7.37. Upstream Bio's Book Value per Sharefor the quarter that ended in Dec. 2024 was $8.77. Hence, Upstream Bio's P/B Ratio of today is 0.84.

Upstream Bio Price-to-Tangible-Book Historical Data

The historical data trend for Upstream Bio's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Price-to-Tangible-Book Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

Price-to-Tangible-Book

1.88

Upstream Bio Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Price-to-Tangible-Book	Get a 7-Day Free Trial			-	-	-	-	1.88

Competitive Comparison of Upstream Bio's Price-to-Tangible-Book

For the Biotechnology subindustry, Upstream Bio's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Upstream Bio's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Upstream Bio's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Upstream Bio's Price-to-Tangible-Book falls into.

Save Embed

;

Save Embed

;

Upstream Bio Price-to-Tangible-Book Calculation

Upstream Bio's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2024 )
	=	7.37	/	8.765
	=	0.84

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Upstream Bio Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.